ArticleJTO clinical and research reports2026
Biopsies Can Predict Lung Adenocarcinoma IASLC Grade: A New Proposal and Grading Pitfalls.
Article in JTO clinical and research reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: The International Association for the Study of Lung Cancer grading system for resected invasive lung adenocarcinoma provides robust prognostic stratification for recurrence risk and overall survival. However, most patients present at advanced stages, where only small biopsy samples are available, leaving no established prognostic tool for such cases. We propose a practical biopsy-based grading method for pulmonary adenocarcinoma. Methods: We analyzed 267 paired biopsies and resections. The following two biopsy grading (bxG) models were tested:•Model 1: Based on the predominant pattern-grade 1 (lepidic), grade 2 (acinar/papillary), grade 3 (solid/micropapillary/complex glandular).•Model 2: Any percentage of high-grade patterns classified as grade 3, regardless of predominance. BxG 1 and 2 are defined as predominant patterns as described.For analysis, grades 1 and 2 were combined (G1-2), and grade 3 was considered a separate category. Diagnostic performance was assessed using resections as the reference standard. Interobserver reliability was evaluated, and discrepant cases were reviewed. Results: Model 1 achieved 79.8% accuracy (sensitivity 57%, specificity 98.6%, positive predictive value [PPV] 97.2%, negative predictive value 73.5%, area under the curve 0.78). Model 2 performed better, with 88.4% accuracy (sensitivity 83.5%, specificity 92.5%, PPV 90.2%, negative predictive value 87.1%, area under the curve 0.89), and was used for further analysis. Discrepancies ( Conclusion: Biopsy grading using the presence of any high-grade pattern correlates well with International Association for the Study of Lung Cancer-based resection grading. Although bxG1 to 2 biopsies may underestimate tumor grade, bxG3 biopsies demonstrate more than 90% specificity and PPV for predicting G3 resections, supporting their potential utility as a clinical prognostic marker.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.